FDA Panel Endorses Pfizer’s Fablyn, With Reservations

Posted by Jacob Goldstein in the Wall Street Journal Health Blog An FDA advisory committee voted 9-3 that the benefits of Pfizer’s osteoporosis drug Fablyn outweigh the risks. But the committee raised lots of concerns during the meeting.